Early evidence has confirmed that gliomas with IDH mutation and 1p/19q codeletion have better survival, whereas glioblastoma with telomerase reverse transcriptase (TERT) promoter mutation have worse survival6. The gene discussed is IDH2; the disease is central nervous system cancer.